It is great news for any drug developer to be granted with Fast Track which normally indicates the medical needs is real, and FDA wants the drug get into market as soon as possible. We are moving into double digits after VMAT2 phase II topline data is reported in two months or sooner
To me the fast track for tardive dyskinesia is great, but I don't know how large the addressable market is. What it does mean is that they will throw a whole bunch of money at it with the required trials. In those trials they should at least get a strong feeling for the drugs effectiveness for other indications, including the holy grail, schizophrenia. If it shows efficacy in the treatment of schizo, we are all rich.